Testosterone supplementation may be effective for the treatment of hypogonadism in men with type 2 diabetes mellitus (T2DM), but the evidence from randomized controlled trials (RCTs) is inconclusive. We aimed to systematically summarize results from intervention studies and assess the effects of testosterone supplementation therapy (TST) on lipid metabolism in RCTs of hypogonadal men with T2DM by meta-analysis. PubMed, Embase, and Cochrane Library databases were searched for studies reporting the effect of TST on lipid metabolism in hypogonadal men with T2DM until December 31, 2016. Seven RCTs from 252 trials, enrolling a total of 612 patients in the experimental and control groups with a mean age of 58.5 years, were included in this study. The pooled results of the meta-analysis demonstrated that TST significantly decreased TC and TG levels in hypogonadal men with T2DM compared with the control group, with mean differences (MDs) of À6.44 (95% CI: À11.82 to À1.06; I 2 = 28%; p = 0.02) and À27.94 (95% CI: À52.33 to À3.54; I 2 = 76%; p = 0.02). Subgroup analyses revealed that the heterogeneity (I 2 = 76%) of TG originated from different economic regions, in which economic development, genetic and environmental factors, and dietary habits affect lipid metabolism of human, with a decrease (I 2 = 45%) in developed countries. Additionally, subgroup analyses showed that TST increased HDL-C level in developing countries compared with the control group (MD = 2.79; 95% CI: 0.73 to 4.86; I 2 = 0%; p = 0.008), but there was no improvement in developed countries (MD = 1.02; 95% CI: À4.55 to 6.60; I 2 = 91%; p = 0.72). However, LDL-C levels were not improved consistently. Because the relationship between lipid metabolism and atherosclerosis is unequivocal, TST, which ameliorates lipid metabolism, may decrease the morbidity and mortality of cardiovascular disease in hypogonadal men with T2DM by preventing atherogenesis.
INTRODUCTION
Due to improved public health conditions worldwide, the average life expectancy of humans is longer than ever before. In addition, more aging men suffer from androgen deficiency (AD) or hypogonadism, which are becoming increasingly important public health issues (Araujo et al., 2004; Taylor et al., 2015) . Hypogonadism can present as many symptoms, including low libido, erectile dysfunction, osteoporosis, muscle weakness, and metabolic disorders. In 2009, the International Society of Andrology (ISA), International Society for the Study of Aging Male (ISSAM), European Association of Urology (EAU), European Academy of Andrology (EAA), and American Society of Andrology (ASA) jointly issued guidelines for late-onset hypogonadism (LOH), recommending a serum T deficiency cutoff value of TT <12 nmol/L (350 ng/dL) and FT <225 pmol/L (6.1 ng/dL) (Wang et al., 2009a) .
A previous study reported a 23.3% prevalence of hypogonadism among 40-to 79-year-old men in the European Male Ageing Study (EMAS) (Tajar et al., 2012) . A higher prevalence of low serum testosterone levels is observed among men with T2DM, ranging from 25 to 40% (Dhindsa et al., 2004; Grossmann et al., 2008) and reaching 50% if obesity is associated (Saboor Aftab et al., 2013) . These patients present with not only glucose intolerance, dyslipidemia, central obesity, hypertension, erectile dysfunction and fatigue, but also cardiovascular disease (CVD), osteoporosis, and chronic depression (Corona et al., 2008; Stanworth & Jones, 2009; Traish et al., 2009; Wang et al., 2011 Wang et al., , 2016 . Dyslipidemia and AD commonly occur in men with T2DM. Moreover, low serum testosterone levels have also been associated with dyslipidemia (Barrett-Connor, 1992) . In addition, AD is known to have an adverse effect on several key risk factors for CVDs, which are somewhat related to dyslipidemia (Jones, 2010) . Thus, testosterone supplementation therapy (TST) is gradually applied in hypogonadal men with T2DM to improve testosterone levels and diabetes complications.
The hypothesis that TST improves measures of lipid metabolism has been tested in numerous clinical studies, which have collectively yielded inconclusive results. Jones et al. found that long-term TST in hypogonadal men with T2DM had many beneficial effects on lipid profile and CVD Janjgava et al., 2014) . However, Aversa et al., (2010) found that total cholesterol (TC) and cholesterol fractions did not change significantly in hypogonadal men with metabolic syndrome after TST. The results from previous meta-analyses on the effects of TST on lipid profile in hypogonadal men with T2DM are conflicting and did not consider the correlation with CVD. Cai et al., (2014) analyzed four RCTs with a total of 277 men with hypogonadism and T2DM and found data indicating that TST decreased triglyceride (TG) levels only. However, another meta-analysis of TST in men with AD from Corona et al., (2016) showed the reduction in TC as well as TG levels and an improvement in high-density lipoprotein (HDL) cholesterol levels. The two previous metaanalyses either included a smaller number of studies or focused on an ordinary patient, not restricting the analysis to hypogonadal men with T2DM.
In this study, we performed a meta-analysis of the effect of TST on lipid metabolism in hypogonadal men with T2DM from strictly selected RCTs, including recent ones. We also evaluated the relationship between lipid metabolism and atherosclerosis, and discussed the possible role of TST in the prevention of CVD.
MATERIALS AND METHODS

Search strategy
We performed an online search of databases, including PubMed, Embase, and the Cochrane Controlled Trials Register, from their inception to December 31, 2016, for all relevant articles. The key words included the following Medical Subject Heading (MeSH) terms and/or text words: testosterone, T, hypogonadism, late-onset hypogonadism, LOH, diabetes, diabetes mellitus, DM, T2DM, andropause, testosterone deficiency, and androgen deficiency. All the above terms were appropriately adjusted for each database. The limits or filters of 'Humans', 'English', 'Clinical trial', 'Controlled clinical trial', and 'Randomized controlled trial (RCT)' were set for corresponding databases during the search process. The titles and abstracts of all potentially relevant articles were read to determine their relevance. Full articles were also examined whether the title and abstract were unclear.
Inclusion and exclusion criteria
Only RCTs that evaluated lipid metabolism in hypogonadal men with T2DM were included in this review. Patients with severe diabetes complications, such as diabetic foot, peripheral neuropathy, and diabetic nephropathy, were not included. The inclusion criteria for this study were as follows. First, the study should be an RCT with placebo or no treatment and present quantitative data on outcome parameters. Second, patients should be diagnosed with T2DM (fasting plasma glucose >7.0 mmol/L at baseline and/or >11.1 mmol/L after a 2-h, 75-g oral glucose tolerance test and an elevated HbA1c level) with a comorbidity of hypogonadism (TT level <350 ng/dL or 12 nmol/ L and FT level <6.1 ng/dL or 225 pmol/L) or a positive screening questionnaire for AD (Morley et al., 2000) . Third, TST was administered to these hypogonadal men with T2DM. Fourth, lipid metabolic parameters, such as TC, TG, HDL, or low-density lipoprotein (LDL), were tested in each trial.
Data extraction
Two investigators independently extracted relevant data using a standardized form. Data extracted from each eligible RCT included demographic information, diagnosis of T2DM and hypogonadism, number of participants, mean age, serum testosterone levels at control and treatment, and type and duration of treatment. Disagreements were resolved by consensus and third party adjudication.
Quality assessment of included studies
Two reviewers independently evaluated the quality of all selected studies using the Cochrane Collaboration's Risk-of-Bias tool (Higgins & Green, 2008) , and disagreements were settled by having a third author evaluate the study. The Cochrane Risk-ofBias Tool contains the following seven types of biases: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. An assessment of high, unclear, or low risk of bias for each item was made. According to a previous systematic review (Cai et al., 2014) , other bias was regarded as low risk if there was no significant difference in the demographic characteristics of the TST and control groups.
Statistical analysis and meta-analysis
Review Manager (version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) and STATA software (version 12.0; Stata Corp LP, College Station, TX, USA) were used for statistical analysis. We considered the outcome measures as continuous data with the same unit of measure and estimated the combined overall effect size as the mean difference (MD) with a random-effects model. We utilized a randomeffects model rather than a fixed-effects model because it takes into account heterogeneity among multiple studies. The confidence intervals (CIs) were established at 95%. Statistical significance was indicated by a two-tailed p value < 0.05. Heterogeneity was evaluated using the chi-square test and the I 2 test in the meta-analysis. p < 0.1 (chi-square test) or I 2 >50%
indicated moderate-to-high heterogeneity (Higgins & Thompson, 2002; Higgins et al., 2003) . Subgroup and sensitivity analyses were also conducted to explore the possible sources of 38 Andrology, 2018, 6, 37-46
heterogeneity, and to test the stability of the outcomes, these analyses were performed by removing one study at a time to ascertain the influence of an individual study on the overall result. We assessed funnel plot asymmetry using Begg's (Begg & Mazumdar, 1994 ) and Egger's (Egger et al., 1997) tests and defined significant publication bias as p < 0.1.
RESULTS
Selected results
We identified 252 potentially relevant articles (57 from PubMed, 77 from Embase, and 118 from the Cochrane Library). After duplicates and articles that did not meet the selection criteria were excluded, 11 eligible articles were carefully reviewed in the initial phase. Subsequently, four articles were excluded, including two for mixing diabetes and metabolic syndrome patients (Aversa et al., 2010; Kalinchenko et al., 2010) , one for mixing eugonadal and hypogonadal men (Boyanov et al., 2003) , and one for being an observational prospective study without a control group (Haider et al., 2014) . Ultimately, seven selected articles with a total of 612 patients were included in the final analysis (Kapoor et al., 2006; Heufelder et al., 2009; Gopal et al., 2010; Jones et al., 2011; Gianatti et al., 2014; Hackett et al., 2014; Janjgava et al., 2014) . The detailed study selection procedure is shown in Fig. 1 .
Study characteristics
Seven studies involving 612 total patients were identified. The characteristics of the seven selected studies are presented in Table 1 . All these studies were RCTs. Six are double-blind, placebo-controlled trials, among which two studies had a crossover design (Kapoor et al., 2006; Jones et al., 2011) , and one is an open-label and single-blind study with no treatment control (Heufelder et al., 2009 ). The majority of the studies were conducted in Europe [two in the UK (Kapoor et al., 2006; Hackett et al., 2014) , one in Germany (Heufelder et al., 2009) , and one in the European Union , and the other three were conducted in India (Gopal et al., 2010) , Georgia (Janjgava et al., 2014) , and Australia (Gianatti et al., 2014) . Only two of these studies were implemented in developing countries (Gopal et al., 2010; Janjgava et al., 2014) , while the rest were in developed countries (Kapoor et al., 2006; Heufelder et al., 2009; Jones et al., 2011; Gianatti et al., 2014; Hackett et al., 2014) . All of the studies were published from 2006 to 2014. The participants in these studies were all middle aged and elderly males with a mean age of 58.5 years. The number of participants randomized into the seven studies included in this meta-analysis ranged from 32 to 186. The treatment durations were as follows: two studies lasted for 12 weeks, two for 24 weeks, one for 30 weeks, one for 40 weeks, and one for 52 weeks. Regarding the methods of TST administration, five studies performed intramuscular injection, and the other two provided TST through the topical gel route. The outcome variables of each study are summarized in Table 2 . All relevant data provided in the trials were converted into the means and standard deviation (SD) according to a previously described method (Hozo et al., 2005) . In cases of missing or incomplete information, all authors of the studies were contacted. Both Prof. Janjgava and Saad (the second author of study implemented by Heufelder et al.) provided relevant original data.
Study quality
Among the selected trials, six provided clear methods with randomized sequence generation. The major problem with these included studies was the lack of detailed information about their allocation concealment method. Only three studies (Kapoor et al., 2006; Heufelder et al., 2009; Gopal et al., 2010) explicitly described their approach, while the others were unclear. All studies had a low risk of bias for incomplete outcome data because no subjects dropped out or withdrew. Because the original protocol of each trial was not obtained, the risk of bias for selective reporting was considered to be unclear. Other bias was regarded as low risk in each study because no statistically significant differences in demographic characteristics were found between the TST and control groups. The details of the quality assessment are illustrated in Figure S1 .
Clinical outcomes
Lipid metabolism parameters, including TC, TG, HDL-C and LDL-C, were evaluated in all seven RCTs, of which four RCTs demonstrated a significant decrease in serum TC levels (Kapoor et al., 2006; Jones et al., 2011; Hackett et al., 2014; Janjgava et al., 2014) , one reported a decrease in only serum TG levels (Heufelder et al., 2009), and one reported a decrease in serum HDL-C and LDL-C after TST . Four forest plots of the meta-analyses were generated to examine the changes in serum TC, TG, HDL-C, and LDL-C levels in the 612 patients (306 in the TST and control group, respectively). The pooled estimates showed that TC (p = 0.02, MD = À6.44, 95% CI À11.82 to À1.06, Fig. 2A ) and TG (p = 0.02, MD = À27.94, 95% CI À52.33 to À3.54, Fig. 2B ) values declined. However, there was no significant difference in HDL-C (p = 0.41, MD = 1.60, 95% CI À2.18 to 5.38, Fig. 2C ) or LDL-C (p = 0.91, MD = À0.19, 95% CI À3.27 to 2.90, Fig. 2D ) between the TST and control groups.
Subgroup analysis
Due to moderate heterogeneity (s 2 = 692.78, v 2 = 25.50, Fig. 2B ; s 2 = 21.88, v 2 = 45.41, p < 0.00001, Fig. 2C ) in the pooled estimate of TG and HDL-C levels, subgroup analyses were conducted according to the regions with different levels of economic development. Consequently, the I 2 value of TG levels decreased to 45% and p increased to 0.12 in subgroup of developed countries (p = 0.007, MD = À32.36, 95% CI À55.67 to À9.05, Fig. 3A ), which indicated that heterogeneity could be explained by diversity (economic development, genetic and environmental factors, and dietary habits) in each area. Similarly, another subgroup analysis revealed a significant increase in HDL-C levels in developing countries (p = 0.008, MD = 2.79, 95% CI 0.73 to 4.86, Fig. 3B) with the I 2 value decreased to 0% and p increased to 0.74 in the subgroup of developing countries. We also pooled the trials and found no significant difference among the LDL-C subgroup in developed or developing countries in the TST and control groups (p = 0.99, MD = À0.03, 95% CI À4.60 to 4.53; p = 0.88, MD = À0.31, 95% CI À4.50 to 3.88 Fig. 3C ) and no heterogeneity (s 2 = 0.00, v 2 = 0.93, p = 0.92, I 2 = 0%; s 2 = 0.00, v 2 = 0.98, p = 0.32, I 2 = 0%, Fig. 3C ), indicating that testosterone could not dictate LDL-C level in hypogonadal men with T2DM. 42 Andrology, 2018, 6, 37-46 Sensitivity analysis and publication bias estimation We performed a sensitivity analysis to assess potential sources of heterogeneity and to test the robustness of our results. The relevant results were in agreement with the initial outcomes upon removing any single study, indicating the stability of our outcome. Meanwhile, in terms of publication bias estimation, we observed symmetry according to Begg's (p = 0.707,  Fig. 4A ) and Egger's test (p = 0.791, Fig. 4B ) in all analyses, indicating no evidence of small study effects.
DISCUSSION
AD is commonly found in hypogonadal men with T2DM (Stanworth & Jones, 2009; Holmboe et al., 2016) . A large body of epidemiological evidence has shown that hypogonadism, which increases sexual dysfunction and alters glucolipid metabolism, leads to an increase in cardiovascular events and causes mortality (Isidori et al., 2005; Araujo et al., 2011) . Interestingly, low serum testosterone levels can predict the development of lipometabolic disturbance (Guay & Jacobson, 2007; Rodriguez et al., 2007) . Fortunately, TST was found to improve the lipid profile of men with AD, as reported by Hromadov a in 1991 (Hromadov a et al., 1991) . Meanwhile, several studies have found that TST does not significantly change serum lipid concentration (Heufelder et al., 2009; Hellstrom et al., 2012) . Therefore, the efficacy of TST in ameliorating lipid metabolism in hypogonadal men with T2DM is controversial. Corona et al., (2016) performed a meta-analysis of observational studies on TST in hypogonadal men, revealing an improvement of lipid profile (reduction in total cholesterol as well as of triglyceride levels and an improvement in HDL cholesterol levels) and suggesting a possible reduction in CVD risk because of the improvement in several CVD risk factors observed in the study. This publication contained relevant observational studies, but not strict RCTs, in which the heterogeneity of patients was large, and the control study was not necessary. In this meta-analysis, we used rigorous inclusion criteria and identified seven double-blind RCTs to assess the effects of TST on lipid metabolism in hypogonadal men with T2DM. Significant improvements were found in TC and TG levels in the treatment group compared with the control group. However, the moderate heterogeneity was found in the pooled estimate of TG. Subgroup analysis disclosed that its heterogeneity might originate from different economic regions with a decrease in heterogeneity in developed countries. Another subgroup analysis showed that HDL-C levels were increased in developing countries in the TST group compared with the control group. The reasonable explanation may be that economic development, genetic and environmental factors, and dietary habits affect lipid metabolism of human in different regions.
The mechanism by which TST improves lipid metabolism is still unclear. It is presumably associated with the aromatization of testosterone, which is enhanced by the increased number of adipocytes in T2DM patients with hypogonadism. Zmuda et al., (1993) confirmed that the aromatization of exogenous testosterone to estradiol is important for maintaining HDL-C concentrations in men and counteracting the effects of TST on hepatic lipoprotein lipase (LPL) activity.
The consequences (myocardial infarction, stroke, and other CVDs) of atherosclerosis are a threat to human health (Rader & Daugherty, 2008) . Lipids play an important role in the mechanisms that transform a healthy vascular wall into an atherosclerotic wall. During atherogenesis, LDL-C particles that are either oxidized or enzymatically degraded adhere to the arterial wall and aggregate. Then, modified LDL-C particles enter the atherogenic pathway, which leads to atherosclerotic plaque formation (Matsuura et al., 2006; Jerome et al., 2008) . However, in this meta-analysis, LDL-C levels exhibited a slight but not statistically significant decrease. We speculate that TST may reduce atherosclerosis in hypogonadal men with T2DM, but this effect may not be mediated by the LDL-C pathway.
One previous meta-analysis indicated that HDL-C may play a critical role in preventing and protecting against atherosclerosis (Toth et al., 2013) . Although the major practical effect of TST is to reduce the serum TC concentration, the plasma HDL-C concentration can be increased (Boyanov et al., 2003; Aversa et al., 2010) , and this effect was confirmed by the present metaanalysis in men in developing countries. Therefore, due to the anti-atherosclerosis activity of HDL-C, TST potentially exhibit preventive and therapeutic effects against atherosclerosis via the HDL-C pathway in hypogonadal men with T2DM.
Hypercholesterolemia is considered one of the main triggers of atherosclerosis. The increase in plasma cholesterol levels results in changes in arterial endothelial permeability, which allows lipids to migrate into the arterial wall, settle in the subendothelial space, and form atheromatous plaque gradually. Monocytes, adhesion molecules, and inflammatory cytokines participate in this process (Sakakura et al., 2013) . In addition, hypertriglyceridemia often coexists with secondary disorders that are independently associated with increased plasma TG levels, such as T2DM, chronic kidney disease, metabolic syndrome, and obesity (Hegele et al., 2014) . Increased plasma TG levels are related to an excess of one or more of the three main types of TG-rich lipoproteins: (i) chylomicrons, (ii) very-lowdensity lipoprotein (VLDL), or (iii) intermediate-density lipoprotein (IDL). The underlying cause is decreased lipolysis of TG in plasma caused by decreased LPL activity in the vascular endothelium. Because the TG/cholesterol ratio in chylomicrons is generally approximately 10 : 1, the plasma TG level is usually close to 10-fold higher than the plasma cholesterol level (Brinton, 2016) .
Hypertriglyceridemia has been considered a promoting factor for atherosclerosis and is now considered an important risk factor for atherosclerotic cardiovascular disease (ASCVD) (Khovidhunkit et al., 2004) . The mechanism of accelerated atherogenesis in hypertriglyceridemia is as follows: First, and most directly, LPL expression in the arterial endothelium and artery wall macrophages lipolyze TG from TG-rich lipoproteins, producing free fatty acids (FFAs), which are proinflammatory, proatherogenic, and procoagulant, on the surface and inside the artery wall (Wang et al., 2009b) ; and second, several types of TGrich lipoproteins are directly atherogenic and their presence in excess is most readily signaled by high plasma TG levels (Ginsberg, 2002; McBride, 2007) . These atherogenic TG-rich lipoproteins are generally called remnants because their TG content has been reduced via lipolysis by LPL in the plasma compartment. In addition, they lose some TGs and become cholesterol enriched by the action of cholesteryl-ester transfer protein (CETP). One proatherogenic effect of these remnants is that they cause senescence of endothelial precursor cells, which lose their ability to maintain vascular endothelial integrity (Liu et al., 2009) . Additionally, remnants stimulate a key early step in atherogenesis by promoting their own uptake by artery wall macrophages, which then become foam cells (Mahley et al., 1985) . The atherogenicity of lipoprotein remnants, which are rich in both TG and cholesterol, markedly increases the risk of ASCVD (Triglyceride Coronary Disease Genetics Consortium & Emerging Risk Factors Collaboration, 2010; Liu et al., 2013) .
According to the results of this meta-analysis, TC and TG are the significant lipid indexes that improved in hypogonadal men with T2DM who received TST. Because treatment with lipid-lowering drugs prevents primary and/or recurrent CVD events that are associated with atherogenesis (Ridker, 2014) , TST, which improves TC and TG levels in hypogonadal men with T2DM, may also prevent atherogenesis and decrease the incidence of ASCVD.
Currently, TST for hypogonadal men remains controversial as an effective treatment for CVD due to a limited number of longterm, placebo-controlled trials and a lack of clear understanding of the related mechanisms. In this meta-analysis, TST was found to improve TC and TG levels, which could prevent and reduce atherosclerosis. Considering that atherosclerosis is the major cause of the development of CVD, preventing or reducing atherosclerosis should effectively decrease the incidence of CVD. TST may become a valid tool for improving lipid metabolic symptoms, reducing atherosclerosis, and thereby decreasing CVD-related morbidity and mortality in hypogonadal men with T2DM. Hence, long-term, large, placebo-controlled trials are needed to address the efficacy of TST in reducing the incidence of CVDs in hypogonadal men with T2DM.
The limitations of this meta-analysis should be considered when interpreting our results. First, the number and sample size of included studies were not sufficiently large, and these studies were geographically scattered. Larger and better-designed RCTs, especially from developing countries, are needed to confirm our conclusion. Second, different dosages, forms, regimens, and preparations of androgens were used in the studies included in this meta-analysis, which may have affected our evaluation of TST. Third, evidence regarding the safety of TST in hypogonadal men with T2DM is limited.
